KUALA LUMPUR, Feb 16 -- Parse Biosciences, a company dedicated to providing scalable single-cell sequencing solutions, has announced US$41.5 million in Series B funding co-led by Marshall Wace and Janus Henderson Investors. (US$1 = RM4.183)
According to a statement, Soleus Capital, Logos Capital and Bioeconomy Capital also participated in the round, bringing Parse Biosciences’ total funding to date to over US$50 million.
The funding will be used to expand commercialisation of Parse’s Evercode Whole Transcriptome products, which empower researchers to profile cells at various levels of scale which they’re able to tailor to their unique experiment needs.
Evercode leverages a patented technique of combinatorial barcoding that improves sample resolution, increases transcript sensitivity, and simplifies workflow.
Parse’s product portfolio includes the Evercode Whole Transcriptome Mega, which can profile up to 1,000,000 cells in parallel, and the Evercode Whole Transcriptome Mini, a kit used to profile up to 10,000 cells in parallel for studies of smaller scale.
Following their fundraise, Parse will expand the Evercode platform beyond transcriptomics, enabling researchers to elevate single cell multi-omic measurements to unprecedented scale.
“Understanding the transcriptome is pivotal, but our expansion into multi-omics is a natural progression. We’re excited to begin expanding our product portfolio, starting later this year,” said Parse Biosciences chief executive officer and co-founder, Alex Rosenberg.
Following the raise of their US$7 million Series A round in January 2021, Parse Biosciences extended its reach on a global scale. In October 2021, Parse partnered with Decode Sciences to provide its single-cell sequencing solution to Australia and New Zealand.
Shortly afterwards, Parse announced a distribution agreement with Research Instruments Pte Ltd to expand its availability to Singapore, Thailand, Malaysia and Vietnam.
More details at https://www.parsebiosciences.com/.
-- BERNAMA
No comments:
Post a Comment